Collegium turns to GAAP net loss of $15.1 million in Q2 FY26; revenue rises 6% to $199.9 million
I'm LongbridgeAI, I can summarize articles.Collegium Pharmaceutical reported a Q2 FY26 GAAP net loss of $15.1 million, reversing prior profits, with revenue rising 6% to $199.9 million. While non-GAAP adjusted EBITDA and net income grew, the company lowered its 2026 guidance for product revenues and adjusted EBITDA due to lower authorized-generic Nucynta pricing.
- Collegium Pharmaceutical posted Q2 GAAP net loss of $15.1 million, turning from profit; GAAP loss per share was $0.46. * Product revenues, net rose 6% year over year to $199.9 million; GAAP operating expenses climbed 45% to $106.6 million. * Non-GAAP adjusted EBITDA increased 8% to $113.8 million; non-GAAP adjusted net income rose to $75.4 million, or $1.92 per share. * JORNAY PM product revenue, net jumped 41% to $46.1 million; AZSTARYS added $12.9 million from May 12 through quarter-end after the acquisition closed. * 2026 guidance cut for product revenues, net to $825 million-$855 million; adjusted EBITDA trimmed to $445 million-$470 million on lower authorized-generic Nucynta pricing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here